CN111195333A - 一种改善睡眠的组合物、睡眠霜及其制备方法和使用方法 - Google Patents
一种改善睡眠的组合物、睡眠霜及其制备方法和使用方法 Download PDFInfo
- Publication number
- CN111195333A CN111195333A CN202010014488.9A CN202010014488A CN111195333A CN 111195333 A CN111195333 A CN 111195333A CN 202010014488 A CN202010014488 A CN 202010014488A CN 111195333 A CN111195333 A CN 111195333A
- Authority
- CN
- China
- Prior art keywords
- parts
- extract
- sleep
- cream
- portions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006071 cream Substances 0.000 title claims abstract description 62
- 239000000203 mixture Substances 0.000 title claims abstract description 53
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 238000000034 method Methods 0.000 title claims abstract description 13
- 239000000284 extract Substances 0.000 claims abstract description 147
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 92
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims abstract description 46
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims abstract description 46
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims abstract description 33
- 206010022437 insomnia Diseases 0.000 claims abstract description 32
- 235000020767 valerian extract Nutrition 0.000 claims abstract description 21
- 229940107131 ginseng root Drugs 0.000 claims abstract description 19
- 229940084801 salvia miltiorrhiza root extract Drugs 0.000 claims abstract description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 36
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 34
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 33
- 239000000843 powder Substances 0.000 claims description 26
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 17
- 229960000458 allantoin Drugs 0.000 claims description 17
- 241000234435 Lilium Species 0.000 claims description 16
- 241001135917 Vitellaria paradoxa Species 0.000 claims description 15
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims description 15
- 239000003995 emulsifying agent Substances 0.000 claims description 15
- 239000002562 thickening agent Substances 0.000 claims description 15
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 14
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 14
- 241000304195 Salvia miltiorrhiza Species 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims description 13
- 239000003974 emollient agent Substances 0.000 claims description 12
- 229940057910 shea butter Drugs 0.000 claims description 12
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 11
- 239000011248 coating agent Substances 0.000 claims description 11
- 238000000576 coating method Methods 0.000 claims description 11
- 239000003755 preservative agent Substances 0.000 claims description 11
- 230000002335 preservative effect Effects 0.000 claims description 11
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 10
- 210000000624 ear auricle Anatomy 0.000 claims description 10
- 239000000171 lavandula angustifolia l. flower oil Substances 0.000 claims description 10
- 229940041616 menthol Drugs 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- 239000010671 sandalwood oil Substances 0.000 claims description 10
- 210000001061 forehead Anatomy 0.000 claims description 9
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims description 8
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 claims description 8
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 8
- 238000001816 cooling Methods 0.000 claims description 8
- 230000001804 emulsifying effect Effects 0.000 claims description 8
- 238000005516 engineering process Methods 0.000 claims description 8
- 210000003128 head Anatomy 0.000 claims description 8
- 229940042585 tocopherol acetate Drugs 0.000 claims description 8
- -1 PEG-100 stearate Chemical compound 0.000 claims description 7
- 240000000111 Saccharum officinarum Species 0.000 claims description 7
- 235000007201 Saccharum officinarum Nutrition 0.000 claims description 7
- 238000000605 extraction Methods 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 238000004898 kneading Methods 0.000 claims description 6
- 238000003825 pressing Methods 0.000 claims description 6
- 239000012530 fluid Substances 0.000 claims description 5
- 239000012528 membrane Substances 0.000 claims description 5
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 5
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 5
- 238000000926 separation method Methods 0.000 claims description 5
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical group OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 claims description 4
- 244000178870 Lavandula angustifolia Species 0.000 claims description 4
- 235000010663 Lavandula angustifolia Nutrition 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 4
- 230000002421 anti-septic effect Effects 0.000 claims description 4
- 238000007906 compression Methods 0.000 claims description 4
- 230000006835 compression Effects 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- 230000006837 decompression Effects 0.000 claims description 4
- 238000007599 discharging Methods 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 235000020710 ginseng extract Nutrition 0.000 claims description 4
- 238000000227 grinding Methods 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 210000000582 semen Anatomy 0.000 claims description 4
- 238000007873 sieving Methods 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 238000000194 supercritical-fluid extraction Methods 0.000 claims description 4
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 claims description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 3
- 229920000742 Cotton Polymers 0.000 claims description 3
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 3
- IUMSDRXLFWAGNT-UHFFFAOYSA-N Dodecamethylcyclohexasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 IUMSDRXLFWAGNT-UHFFFAOYSA-N 0.000 claims description 3
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 3
- 239000004902 Softening Agent Substances 0.000 claims description 3
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 claims description 3
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 3
- 229930182478 glucoside Natural products 0.000 claims description 3
- 229940075529 glyceryl stearate Drugs 0.000 claims description 3
- 229940100460 peg-100 stearate Drugs 0.000 claims description 3
- 229940104256 sodium taurate Drugs 0.000 claims description 3
- 210000002421 cell wall Anatomy 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 29
- 210000005036 nerve Anatomy 0.000 abstract description 19
- 230000003860 sleep quality Effects 0.000 abstract description 13
- 230000001976 improved effect Effects 0.000 abstract description 9
- 230000005284 excitation Effects 0.000 abstract description 6
- 238000010521 absorption reaction Methods 0.000 abstract description 4
- 230000007830 nerve conduction Effects 0.000 abstract description 3
- 230000009044 synergistic interaction Effects 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 30
- 239000000047 product Substances 0.000 description 29
- 210000003491 skin Anatomy 0.000 description 19
- 239000002994 raw material Substances 0.000 description 12
- 239000003814 drug Substances 0.000 description 11
- 230000001737 promoting effect Effects 0.000 description 10
- 210000004556 brain Anatomy 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 208000019901 Anxiety disease Diseases 0.000 description 8
- 230000036506 anxiety Effects 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 230000017531 blood circulation Effects 0.000 description 8
- 230000001914 calming effect Effects 0.000 description 8
- 230000002936 tranquilizing effect Effects 0.000 description 8
- 230000006870 function Effects 0.000 description 7
- 230000000147 hypnotic effect Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000000341 volatile oil Substances 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 5
- 240000008866 Ziziphus nummularia Species 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 230000036407 pain Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 229960003987 melatonin Drugs 0.000 description 4
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 230000011514 reflex Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 3
- 206010062519 Poor quality sleep Diseases 0.000 description 3
- 208000001431 Psychomotor Agitation Diseases 0.000 description 3
- 206010038743 Restlessness Diseases 0.000 description 3
- 208000010340 Sleep Deprivation Diseases 0.000 description 3
- 239000002249 anxiolytic agent Substances 0.000 description 3
- 230000000949 anxiolytic effect Effects 0.000 description 3
- 210000003710 cerebral cortex Anatomy 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 208000019116 sleep disease Diseases 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 description 2
- 206010001497 Agitation Diseases 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 206010012374 Depressed mood Diseases 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 229930195210 Ophiopogon Natural products 0.000 description 2
- 244000248557 Ophiopogon japonicus Species 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 240000004371 Panax ginseng Species 0.000 description 2
- YMGFTDKNIWPMGF-QHCPKHFHSA-N Salvianolic acid A Natural products OC(=O)[C@H](Cc1ccc(O)c(O)c1)OC(=O)C=Cc2ccc(O)c(O)c2C=Cc3ccc(O)c(O)c3 YMGFTDKNIWPMGF-QHCPKHFHSA-N 0.000 description 2
- YMGFTDKNIWPMGF-UCPJVGPRSA-N Salvianolic acid A Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C(=C(O)C(O)=CC=1)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 YMGFTDKNIWPMGF-UCPJVGPRSA-N 0.000 description 2
- 240000009022 Smilax rotundifolia Species 0.000 description 2
- 235000003205 Smilax rotundifolia Nutrition 0.000 description 2
- 206010043268 Tension Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000007177 brain activity Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 238000013021 overheating Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 208000024335 physical disease Diseases 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 229930183842 salvianolic acid Natural products 0.000 description 2
- 208000020685 sleep-wake disease Diseases 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- SMRPGWBDLOQHOS-UHFFFAOYSA-N 5-[4,5-dihydroxy-6-(hydroxymethyl)-3-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxy-3,4-dihydroxy-6-[[9-hydroxy-4-(hydroxymethyl)-4,6a,6b,8a,11,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1H-picen-3-yl]oxy]oxane-2-carboxylic acid Chemical compound OC1C(O)C(O)C(C)OC1OC1C(OC2C(OC(C(O)C2O)C(O)=O)OC2C(C3C(C4C(C5(CCC6(C)C(O)CC(C)(C)CC6C5=CC4=O)C)(C)CC3)(C)CC2)(C)CO)OC(CO)C(O)C1O SMRPGWBDLOQHOS-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000002381 Brain Hypoxia Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 229910021532 Calcite Inorganic materials 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 235000009024 Ceanothus sanguineus Nutrition 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 206010011971 Decreased interest Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 240000003553 Leptospermum scoparium Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 235000005135 Micromeria juliana Nutrition 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 206010029412 Nightmare Diseases 0.000 description 1
- 208000008705 Nocturnal Myoclonus Syndrome Diseases 0.000 description 1
- 206010057178 Osteoarthropathies Diseases 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 description 1
- 240000000513 Santalum album Species 0.000 description 1
- 235000008632 Santalum album Nutrition 0.000 description 1
- 240000002114 Satureja hortensis Species 0.000 description 1
- 235000007315 Satureja hortensis Nutrition 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 244000126014 Valeriana officinalis Species 0.000 description 1
- 235000013832 Valeriana officinalis Nutrition 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229910052586 apatite Inorganic materials 0.000 description 1
- 238000000222 aromatherapy Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 239000002734 clay mineral Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 150000007955 flavonoid glycosides Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000004313 glare Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 231100000546 inhibition of ovulation Toxicity 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 210000004560 pineal gland Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 description 1
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 description 1
- PPRSVUXPYPBULA-UHFFFAOYSA-N saponin A Natural products CC1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(OC6OC(CO)C(O)C(O)C6=O)C(C)(C)C5CCC34C)C2C1)C(=O)O PPRSVUXPYPBULA-UHFFFAOYSA-N 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 238000004781 supercooling Methods 0.000 description 1
- 238000004808 supercritical fluid chromatography Methods 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 235000016788 valerian Nutrition 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
- A61K35/10—Peat; Amber; Turf; Humus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/84—Valerianaceae (Valerian family), e.g. valerian
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8967—Lilium, e.g. tiger lily or Easter lily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/965—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of inanimate origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/805—Corresponding aspects not provided for by any of codes A61K2800/81 - A61K2800/95
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Birds (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Anesthesiology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种改善睡眠的组合物、睡眠霜及其制备方法和使用方法,该组合物包括:γ‑氨基丁酸0.2份‑3份、酸枣仁提取物0.5‑3份、麦冬根提取物0.5‑5份、土茯苓提取物0.1‑1份、丹参根提取物0.1‑1份、人参根提取物0.1‑2份、缬草提取物1‑2份、龙骨1‑5份。本发明的改善睡眠的组合物主要是外用涂敷、治疗失眠的产品,不注射,不口服,只需轻轻涂抹,经皮吸收,可辅助快速睡眠;组合物中各组分之间具有协同增效作用,通过修复神经传导信号的失衡,抑制神经兴奋,舒缓放松神经,精心安神,从而改善人的入睡困难、失眠多梦、深度睡眠少、睡眠质量不高等情况。
Description
技术领域
本发明涉及化妆品技术领域,尤其涉及一种改善睡眠的组合物、睡眠霜及其制备方法和使用方法。
背景技术
调查显示,有78%的人群自认为睡不好觉,受失眠困扰的人占比如此之高,说明“睡眠不好”已经成了这个社会的常态。有的人经常无法入睡或者无法保持睡眠状态,严重导致睡眠不足,这称为入睡和维持睡眠障碍;有的人是经常不能获得正常睡眠为特征,由各种原因导致的入睡困难、睡眠深度或频度过短(浅睡性失眠)、早醒及睡眠时间不足或质量差的一种病症。
睡眠不足,对人体健康可造成不利影响,主要危害有:(1)植物神经功能紊乱,表现为心慌、出汗、血压升高、头晕、头痛、学习和工作效率低下等。(2) 内分泌功能紊乱,可出现面部痤疮,血脂、血糖的代谢紊乱。(3)可导致精神焦虑、抑郁,表现为内心紧张不安、缺乏安全感、坐立不安、兴趣丧失、情绪低落、自责等。(4)免疫力明显的感觉降低,由此会导致种种疾病发生,如神经衰弱、感冒、胃肠疾病等。
失眠是一种非正常的睡眠状态,要克服这种障碍,我们必须先找到导致失眠的原因,才能对症下药,导致失眠的原因大致可以归为以下五大类:(1)生理造成的失眠。环境的改变,会使人产生生理上的反应,如乘坐车、船、飞机时睡眠环境的变化;卧室内强光、噪声、过冷或过热都可能使人失眠。(2)心理因素导致的失眠。心理因素如焦虑、烦躁不安或情绪低落、心情不愉快等,都是引起失眠的重要原因。(3)其他物质和药物引起的失眠。服用中枢兴奋药物可导致失眠,如减肥药、避孕药等。长期服用安眠药,一旦戒掉,也会出现戒断症状——睡眠浅,噩梦多。(4)对失眠的恐惧引起的失眠。城市娱乐生活过多,人如果在睡前玩手机、IPAD等,也会造成睡眠困难,越睡不着越着急,一着急心理压力就更大,就更难入睡。(5)身体疾病造成的失眠。导致失眠的身体疾病有脑部疾病、心脏病、高血压、睡眠呼吸暂停综合征、甲状腺功能亢进、夜间肌阵挛综合征、肾病、哮喘、溃疡病、关节炎、骨关节病、肠胃病等。
目前,市场上治疗睡眠不好问题的主要产品有:(1)以褪黑素为主要原料的睡眠产品,可以口服,也可以通过喷雾或透皮贴剂的方式给药,但褪黑素具有一定的抑制排卵作用,影响生育;长期使用褪黑素会导致松果体不再正常分泌,从而抑制腺体的正常分泌,导致分泌功能紊乱,并产生依赖性;影响精神,促进脑血管收缩,增加中风危险;长期使用还会导致致癌的风险。(2)香薰精油类产品,虽然精油用于头部按摩,可改善睡眠,但其只对于头部肌肉紧张导致的有效,对于其他睡眠障碍方面的治疗,有效率低。(3)其他药物,如安定片、中成药等等,主要是口服,服用后,会产生耐药性和副作用。
发明内容
为了克服现有技术的不足,本发明提供一种改善睡眠的组合物,可辅助快速睡眠,修复神经,缓解紧张情绪,起到良好的改善睡眠的功效。
本发明还提供一种采用上述改善睡眠的组合物所制成的睡眠霜,其安全性好,不经胃肠吸收,副作用小,而是经皮吸收,可辅助快速睡眠。
本发明还提供一种上述睡眠霜的制备方法。
本发明还提供一种上述睡眠霜在改善人体睡眠中的使用方法。
本发明采用如下技术方案实现:
一种改善睡眠的组合物,包括如下重量份的组分:
γ-氨基丁酸0.2份-3份、酸枣仁提取物0.5-3份、麦冬根提取物0.5-5份、土茯苓提取物0.1-1份、丹参根提取物0.1-1份、人参根提取物0.1-2份、缬草提取物1-2份、龙骨1-5份。
组合物选用了多种提取物作为材料,使用其有效活性成分,有利于皮肤的吸收,其中,酸枣仁提取物主用于安神作用,辅以龙骨、土茯苓提取物,能够增强酸枣仁提取物的镇静、安眠等功效,配合γ-氨基丁酸,有效抑制中枢神经系统过度兴奋;缬草提取物加强大脑皮层的抑制过程,减低反射兴奋性;丹参根提取物、麦冬根提取物等成分能提升脑部供血功能,改善脑缺血和低氧的情况;人参根提取物升阳固本,调理整体循环,从而可辅助快速睡眠,修复神经,缓解紧张情绪,起到良好的改善睡眠的功效。
具体的,上述各组分的功效如下:
γ-氨基丁酸,是一种天然存在的非蛋白质氨基酸,在人体大脑皮质、海马、丘脑、基底神经节和小脑中起重要作用,并对机体的多种功能具有调节作用,其广泛分布于动、植物体内。γ-氨基丁酸可抑制中枢神经系统过度兴奋,对脑部具有安定作用,进而促进放松和消除神经紧张;可降低神经元活性,防止神经细胞过热,能结合抗焦虑的脑受体并使之激活,然后与其他物质协同作用,阻止与焦虑相关的信息抵达脑指示中枢,可从根本上镇静神经,从而达到抗焦虑、改善睡眠的效果。
酸枣仁提取物,是以酸枣仁为原料提取的产品,酸枣仁内富含脂肪油,大部分为不饱和脂肪酸,还含有酸枣仁皂苷A、B、BI、黄酮苷、酸枣多糖等物质,主要有镇静、催眠、镇痛、抗惊愕、增强免疫功能等功效,研究表明,酸枣仁苷类对抗心肌缺血、调节血脂、改善冠状动脉硬化、抗心律失常的作用比较突出。
麦冬根提取物,具有养阴生津,润肺清心等功效,可用于治疗津伤口渴、心烦失眠、内热消渴等症。
土茯苓提取物,具有利水渗湿,健脾,安神的功效。
丹参根提取物,丹参根是丹参的主要成药部分,取自植物丹参的根部制作而成,丹参具有活血化瘀、清心除烦、养心安神等功效,其提取物是丹参精华浓缩,在提取过程中,最大限度的保留了丹参植物中原有的丹酚酸和迷迭香酸等抗氧化成分;丹酚酸有很强的抗氧化作用,能有效清除人体内的氧自由基,抑制脂质过氧化反应,提高人体免疫机能。
人参根提取物,是从五加科植物人参的根提取而得的全水溶性天然化妆品原料。它能延缓皮肤衰老,防止皮肤干燥脱水,增加皮肤的弹性,从而起到保护皮肤光泽柔嫩,防止和减少皮肤皱纹的作用。
缬草提取物,是以缬草根为原料提取的产品,其具有安神,理气,止痛等功效,还能加强大脑皮层的抑制过程,减低反射兴奋性,解除平滑肌痉挛,使其具有镇静、催眠、解痉、镇痛作用。
龙骨,由磷灰石、方解石及少量黏土矿物组成,其主要成分为碳酸钙、磷酸钙等物质,具有镇心安神,平肝潜阳,固涩,收敛等功效。
进一步地,所述γ-氨基丁酸的制备方法是采用破壁技术和分子膜活化定向技术的结合,将甘蔗经过破壁、分离、提取、浓缩的步骤所制得。
甘蔗,除了内含有丰富的糖分和水分,还含有酪氨酸、胱氨酸、苯丙氨酸、γ-氨基丁酸等多种氨基酸,其中,甘蔗中含有本发明所需的γ-氨基丁酸,γ- 氨基丁酸通过采用破壁技术和分子膜活化定向技术从甘蔗中所提取,使得γ-氨基丁酸能够最大量的提取出来,并在最大限度上保持了γ-氨基丁酸的活性,提高γ-氨基丁酸的含量和纯度,将大分子团的物质转化为小分子团,让γ-氨基丁酸的有效性能直接最大化,并且使得γ-氨基丁酸的脂溶性增强,轻易穿过脂膜,可以迅速渗透至人体内,有利于人体对γ-氨基丁酸的吸收和利用。本发明的γ- 氨基丁酸的另一个获取途径是在酸枣仁中提取所得,采用破壁技术和分子膜活化定向技术的结合,将酸枣仁经过破壁、分离、提取、浓缩的步骤所制得,即本发明的γ-氨基丁酸从酸枣仁、甘蔗中所提取,所得的γ-氨基丁酸对修复神经,缓解紧张情绪、改善睡眠、帮助促进睡眠等作用效果更好。
失眠、焦虑抑郁症引发根源是神经递质紊乱,而本发明所采用的γ-氨基丁酸具有以下的作用原理:1、抗焦虑、抑郁、压力、调节情绪,缓解神经紧张,促使精神安定。2、抑制神经兴奋,舒缓放松神经,静心安神。3、修复神经传导信号的失衡,能结合抗焦虑的脑受体并使之激活,与另外一些物质协同作用,阻止与焦虑相关的信息抵达脑指示中枢,可从根本上镇静神经。4、具有改善睡眠、帮助促进睡眠作用,透皮吸收足量的γ-氨基丁酸容易进入深度睡眠,对容易胡思乱想的大脑停不下来有调节作用,γ-氨基丁酸可促使大脑冷静下,是大脑过度兴奋的一把刹车,“大脑天然镇静剂”。5、提高脑活力、改善记忆、促进脑部血流。6、营养神经细胞、增加生长激素分泌。
因此,γ-氨基丁酸的作用原理可以总结为以下六个方面:神经调节,辅助调节血压,缓解疲劳,舒缓压力,激发脑活力,改善睡眠。
进一步地,所述组合物还包括如下重量份的组分:百合1-3份、首乌藤1-3 份、苦参0.5-1份、茯神提取物1-3份、艾叶提取物1-3份、琥珀1-3份。
其中,百合,具有养阴润肺、清心安神、镇静催眠、增强免疫功能等功效,其成分中的百合苷,可以有效改善睡眠质量,提高人体机能。
首乌藤,具有养血安神、祛风通络、消炎抗菌、降低血脂的功效,可用于治疗失眠多梦、心神不宁、血虚身痛、风湿痹痛、皮肤瘙痒等症。
苦参,取于苦参的干燥根部,其具有清热燥湿、祛风杀虫等功效,对结核杆菌、痢疾杆菌、金黄色葡萄球菌、大肠杆菌均有抑制作用、对多种皮肤真菌也有抑制作用。
茯神提取物,具有宁心、安神、利水等功效,用于心虚惊悸、健忘、失眠、惊痫、小便不利等症状。
艾叶提取物,可以入脾经和肝经,具有行气止痛和温中散寒以及止血等多种功效,其含有一些天然化学成分挥发油,它还含有一些黄酮类化合物或天然多糖,吸收以后可以促进身体代谢,也能加快人体的免疫细胞再生,能防止一些化学成分对人体免疫系统的破坏。
琥珀,含有琥珀酸和琥珀树脂,其有效成分能迅速地渗透到皮肤下,深入到细胞组织中,促进血液循环,减轻肌肉疼痛等等。它主要有镇静安神、散瘀止痛、利水通淋、去翳明目等功效。
进一步地,所述组合物还包括如下重量份的组分:牛油果树果脂5-15份、薄荷脑0.1-1份、薰衣草油0.1-1份、檀香油0.1-1份、尿囊素0.01-0.1份。
其中,牛油果树果脂,从牛油果树的果实中提取而成,含有丰富的不饱和脂肪酸,能够加强皮肤的保湿能力,对干性皮肤即角质受损的肌肤能加以滋润,同时可以调节产品的流动性,改善粘度,提高产品的感官品质和使用肤感。
薄荷脑,能够选择性地刺激人体皮肤或黏膜的冷觉感受器,产生冷觉反射和冷感,引起皮肤黏膜血管收缩,促进血液循环等功效。
薰衣草油,能滋润肌肤、促进皮肤更新,使皮肤白嫩,并具有抗惊厥、镇静、抗脂质过氧化、利胆等作用。
檀香油,具有促进皮肤细胞生长的作用,对伤口或疤痕可以迅速复原,进而具有弹性、紧缩等作用,并有放松、镇静的效果,解除精神紧张,带来祥和的气氛,令人增加充实感,放松全身等功效。
尿囊素具有保护组织、亲水、吸水和防止水分散发等作用,同时尿囊素可以促进组织生长,细胞新陈代谢,软化角质层蛋白。
本发明提供一种睡眠霜,其包括如下重量份的组分:
γ-氨基丁酸0.2份-3份、酸枣仁提取物0.5-3份、麦冬根提取物0.5-5份、土茯苓提取物0.1-1份、丹参根提取物0.1-1份、人参根提取物0.1-2份、缬草提取物1-2份、龙骨1-5份、尿囊素0.01-0.1份、EDTA二钠0.01-0.1份、甘油1-3 份、丙二醇1-3份、丁二醇1-3份、防腐剂0.01-0.1份、增稠剂1-3份、乳化剂 0.5-2份、柔润剂1-3份、水30-60份。
进一步地,所述防腐剂为对羟基苯乙酮、羟苯甲酯中的一种或者多种组合;所述增稠剂为丙烯酸羟乙酯/丙烯酰二甲基牛磺酸钠共聚物。
进一步地,所述乳化剂为辛酸/癸酸甘油三酯、PEG-100硬脂酸酯、甘油硬脂酸酯、C14-22醇、C12-20烷基葡糖苷中的一种或者多种组合;所述柔润剂为环五聚二甲基硅氧烷、环己硅氧烷中的一种或者多种组合。
进一步地,所述睡眠霜还包括如下重量份的组分:
百合1-3份、首乌藤1-3份、苦参0.5-1份、茯神提取物1-3份、艾叶提取物1-3份、薄荷脑0.1-1份、琥珀1-3份、牛油果树果脂5-15份、薰衣草油0.1-1 份、檀香油0.1-1份、生育酚乙酸酯0.01-0.1份。
本发明的一种睡眠霜的制备方法,包括如下制备步骤:
将百合、首乌藤、苦参投入超临界流体萃取装置,经过流体压缩、萃取、减压、分离的步骤,得到萃取液;
将龙骨、琥珀分别研磨粉碎后,过60目-80目筛,得到龙骨细粉和琥珀细粉;
将甘油、丙二醇、丁二醇、尿囊素、牛油果树果脂、生育酚乙酸酯、水放入乳化锅内,加热至70℃-80℃,均质10min-15min,冷却至40℃-50℃,形成第一混合物;
将酸枣仁提取物、麦冬根提取物、土茯苓提取物、丹参根提取物、人参根提取物、缬草提取物、茯神提取物、艾叶提取物、薰衣草油、檀香油、薄荷脑、萃取液、γ-氨基丁酸、乳化剂依次投入第一混合物,乳化均质30min-50min,形成第二混合物;
向第二混合物中依次加入防腐剂、柔润剂、EDTA二钠、龙骨细粉、琥珀细粉、增稠剂,搅拌混合10min-15min,冷却出料。
本发明提供一种睡眠霜的使用方法,其包括:
在睡觉前2h-3h,使用酒精棉将耳背、耳根、耳垂和额头擦干净,晾干;
对于轻度暂时性失眠者,挤出一颗黄豆大小的睡眠霜膏体,分成均匀的两部分,分别涂在两个耳背后面和耳垂前后侧;挤出一颗黄豆大小的睡眠霜膏体,沿着发际线均匀涂抹于额头上,按摩至吸收;按摩头部上的翳明穴和睡眠穴,揉并点按穴位,按摩时间为3min-5min;
对于重度暂时性失眠者,挤出一颗黄豆大小的睡眠霜膏体,分成均匀的两部分,分别涂在两个耳背后面和耳垂前后侧;挤出二颗黄豆大小的睡眠霜膏体,沿着发际线均匀涂抹于额头上,按摩至吸收;按摩头部上的翳明穴和睡眠穴,揉并点按穴位,按摩时间为10min-15min。
相比现有技术,本发明的有益效果在于:
本发明的改善睡眠的组合物主要是外用涂敷、治疗失眠的产品,不注射,不口服,只需轻轻涂抹,经皮吸收,可辅助快速睡眠;组合物中各组分之间具有协同增效作用,通过修复神经传导信号的失衡,抑制神经兴奋,舒缓放松神经,精心安神,从而改善人的入睡困难、失眠多梦、深度睡眠少、睡眠质量不高等情况。
本发明所提供的睡眠霜,安全性好,不经胃肠吸收,副作用小,而是经皮吸收,配合涂抹和按摩等方式,能加速各有效成分的渗入,增强药物的效力,使药物能够更好发挥其功效,起效快,具有安神镇惊,解郁助眠,起到良好的改善睡眠的功效。
本发明所提供的睡眠霜的使用方法,针对不同类型的失眠者,用药量不同,以便于用户通过使用本发明的产品后,可以有效、快速地改善睡眠质量,并养成良好的睡眠习惯。
附图说明
图1为本发明的改善睡眠的组合物的实施例1的产品渗透皮肤测试图;
图2为图1所示的手指再次涂敷有实施例1的产品的末梢血管血液流动图。
具体实施方式
下面,结合具体实施方式,对本发明做进一步描述,需要说明的是,在不相冲突的前提下,以下描述的各实施例之间或各技术特征之间可以任意组合形成新的实施例。
本发明提供一种改善睡眠的组合物,包括如下重量份的组分:γ-氨基丁酸 0.2份-3份、酸枣仁提取物0.5-3份、麦冬根提取物0.5-5份、土茯苓提取物0.1-1 份、丹参根提取物0.1-1份、人参根提取物0.1-2份、缬草提取物1-2份、龙骨 1-5份。
该改善睡眠的组合物还包括如下重量份的组分:百合1-3份、首乌藤1-3份、苦参0.5-1份、茯神提取物1-3份、艾叶提取物1-3份、薄荷脑0.1-1份、琥珀 1-3份、牛油果树果脂5-15份、薰衣草油0.1-1份、檀香油0.1-1份、尿囊素0.01-0.1 份。
可选的,龙骨采用龙骨粉,龙骨粉为60目-80目的粉末;琥珀采用琥珀粉,琥珀粉为60目-80目的粉末;百合、首乌藤、苦参等中草药采用超临界流体方法萃取,在接近室温(35℃~40℃)及CO2气体笼罩下进行提取,有效地防止了热敏性物质的氧化和逸散。
上述的改善睡眠的组合物的制备方法为:将各组分加入至搅拌器内,混合均匀,即可制得本发明的改善睡眠的组合物。
上述的改善睡眠的组合物主要用于制备睡眠霜等产品,也可以单独使用,如直接涂于两个耳背后面和耳垂前后侧,并通过按摩使其快速吸收。
本发明提供一种睡眠霜,其包括如下重量份的组分:
γ-氨基丁酸0.2份-3份、酸枣仁提取物0.5-3份、麦冬根提取物0.5-5份、土茯苓提取物0.1-1份、丹参根提取物0.1-1份、人参根提取物0.1-2份、缬草提取物1-2份、龙骨1-5份、尿囊素0.01-0.1份、EDTA二钠0.01-0.1份、甘油1-3 份、丙二醇1-3份、丁二醇1-3份、防腐剂0.01-0.1份、增稠剂1-3份、乳化剂 0.5-2份、柔润剂1-3份、水30-60份。
该睡眠霜还包括如下重量份的组分:百合1-3份、首乌藤1-3份、苦参0.5-1 份、茯神提取物1-3份、艾叶提取物1-3份、薄荷脑0.1-1份、琥珀1-3份、牛油果树果脂5-15份、薰衣草油0.1-1份、檀香油0.1-1份、生育酚乙酸酯0.01-0.1 份。
可选的,所述防腐剂为对羟基苯乙酮、羟苯甲酯中的一种或者多种组合;所述增稠剂为丙烯酸羟乙酯/丙烯酰二甲基牛磺酸钠共聚物。所述乳化剂为辛酸/ 癸酸甘油三酯、PEG-100硬脂酸酯、甘油硬脂酸酯、C14-22醇、C12-20烷基葡糖苷中的一种或者多种组合;所述柔润剂为环五聚二甲基硅氧烷、环己硅氧烷中的一种或者多种组合。
上述的睡眠霜的制备方法,包括如下制备步骤:
将百合、首乌藤、苦参投入超临界流体萃取装置,经过流体压缩、萃取、减压、分离的步骤,得到萃取液;
将龙骨、琥珀分别研磨粉碎后,过60目-80目筛,得到龙骨细粉和琥珀细粉;
将甘油、丙二醇、丁二醇、尿囊素、牛油果树果脂、生育酚乙酸酯、水放入乳化锅内,加热至70℃-80℃,均质10min-15min,冷却至40℃-50℃,形成第一混合物;
将酸枣仁提取物、麦冬根提取物、土茯苓提取物、丹参根提取物、人参根提取物、缬草提取物、茯神提取物、艾叶提取物、薰衣草油、檀香油、薄荷脑、萃取液、γ-氨基丁酸、乳化剂依次投入第一混合物,乳化均质30min-50min,形成第二混合物;
向第二混合物中依次加入防腐剂、柔润剂、EDTA二钠、龙骨细粉、琥珀细粉、增稠剂,搅拌混合10min-15min,冷却出料。
本发明还提供一种睡眠霜的使用方法,其包括:
在睡觉前2h-3h,使用酒精棉将耳背、耳根、耳垂和额头擦干净,晾干;
对于轻度暂时性失眠者,挤出一颗黄豆大小的睡眠霜膏体,分成均匀的两部分,分别涂在两个耳背后面和耳垂前后侧;挤出一颗黄豆大小的睡眠霜膏体,沿着发际线均匀涂抹于额头上,按摩至吸收;按摩头部上的翳明穴和睡眠穴,揉并点按穴位,按摩时间为3min-5min;
对于重度暂时性失眠者,挤出一颗黄豆大小的睡眠霜膏体,分成均匀的两部分,分别涂在两个耳背后面和耳垂前后侧;挤出二颗黄豆大小的睡眠霜膏体,沿着发际线均匀涂抹于额头上,按摩至吸收;按摩头部上的翳明穴和睡眠穴,揉并点按穴位,按摩时间为10min-15min。
以下是本发明具体的实施例,在下述实施例中所采用的原材料、设备等除特殊限定外均可以通过购买方式获得。
实施例1:
取0.2份γ-氨基丁酸、0.5份酸枣仁提取物、0.5份麦冬根提取物、0.1份土茯苓提取物、0.1份丹参根提取物、0.1份人参根提取物、1份缬草提取物、1份龙骨粉放入搅拌器内,混合均匀,制得改善睡眠的组合物一。
实施例2:
取1.5份γ-氨基丁酸、2份酸枣仁提取物、2.5份麦冬根提取物、0.5份土茯苓提取物、0.5份丹参根提取物、1份人参根提取物、1.5份缬草提取物、2.5份龙骨粉放入搅拌器内,混合均匀,制得改善睡眠的组合物二。
实施例3:
取3份γ-氨基丁酸、3份酸枣仁提取物、5份麦冬根提取物、1份土茯苓提取物、1份丹参根提取物、2份人参根提取物、2份缬草提取物、5份龙骨粉放入搅拌器内,混合均匀,制得改善睡眠的组合物三。
实施例4:
取0.2份γ-氨基丁酸、0.5份酸枣仁提取物、0.5份麦冬根提取物、0.1份土茯苓提取物、0.1份丹参根提取物、0.1份人参根提取物、1份缬草提取物、1份龙骨粉、百合2份、首乌藤1份、苦参1份、茯神提取物1份、艾叶提取物2 份、琥珀粉2份放入搅拌器内,混合均匀,制得改善睡眠的组合物四。
实施例5:
取1份γ-氨基丁酸、1.2份酸枣仁提取物、2份麦冬根提取物、1份土茯苓提取物、1份丹参根提取物、1份人参根提取物、1份缬草提取物、1份龙骨粉、牛油果树果脂6份、薄荷脑0.5份、薰衣草油1份、檀香油1份、尿囊素0.1份放入搅拌器内,混合均匀,制得改善睡眠的组合物五。
实施例6:
取3份γ-氨基丁酸、3份酸枣仁提取物、5份麦冬根提取物、1份土茯苓提取物、1份丹参根提取物、2份人参根提取物、2份缬草提取物、5份龙骨粉、百合2份、首乌藤1份、苦参1份、茯神提取物1份、艾叶提取物2份、薄荷脑0.5份、琥珀粉2份、牛油果树果脂6份、薰衣草油0.5份、檀香油0.5份、尿囊素0.05份放入搅拌器内,混合均匀,制得改善睡眠的组合物六。
实施例7:
一种睡眠霜包括如下重量份的组分:
γ-氨基丁酸0.2份、酸枣仁提取物0.5份、麦冬根提取物0.5份、土茯苓提取物0.1份、丹参根提取物0.1份、人参根提取物0.1份、缬草提取物1份、龙骨1份、尿囊素0.01份、EDTA二钠0.01份、甘油1份、丙二醇1份、丁二醇 1份、防腐剂0.01份、增稠剂1份、乳化剂0.5份、柔润剂1份、水30份。
该睡眠霜采用如下方法制备:
将百合、首乌藤、苦参投入超临界流体萃取装置,经过流体压缩、萃取、减压、分离的步骤,得到萃取液;将龙骨、琥珀分别研磨粉碎后,过70目筛,得到龙骨细粉和琥珀细粉;
将甘油、丙二醇、丁二醇、尿囊素、牛油果树果脂、生育酚乙酸酯、水放入乳化锅内,加热至75℃,均质10min,冷却至45℃,形成第一混合物;
将酸枣仁提取物、麦冬根提取物、土茯苓提取物、丹参根提取物、人参根提取物、缬草提取物、茯神提取物、艾叶提取物、薰衣草油、檀香油、薄荷脑、萃取液、γ-氨基丁酸、乳化剂依次投入第一混合物,乳化均质35min,形成第二混合物;
向第二混合物中依次加入防腐剂、柔润剂、EDTA二钠、龙骨细粉、琥珀细粉、增稠剂,搅拌混合12min,冷却出料。
实施例8:
与实施例7不同在于:
该睡眠霜包括如下重量份的组分:
γ-氨基丁酸1.5份、酸枣仁提取物2份、麦冬根提取物2.5份、土茯苓提取物0.5份、丹参根提取物0.5份、人参根提取物1份、缬草提取物1.5份、龙骨 3份、尿囊素0.05份、EDTA二钠0.05份、甘油2份、丙二醇2份、丁二醇2 份、防腐剂0.05份、增稠剂2份、乳化剂1份、柔润剂2份、水45份。
实施例9:
与实施例7不同在于:
该睡眠霜包括如下重量份的组分:
γ-氨基丁酸3份、酸枣仁提取物3份、麦冬根提取物5份、土茯苓提取物 1份、丹参根提取物1份、人参根提取物2份、缬草提取物2份、龙骨5份、尿囊素0.1份、EDTA二钠0.1份、甘油3份、丙二醇3份、丁二醇3份、防腐剂 0.1份、增稠剂3份、乳化剂2份、柔润剂3份、水60份。
实施例10:
与实施例7不同在于:
该睡眠霜包括如下重量份的组分:
γ-氨基丁酸0.2份、酸枣仁提取物0.5份、麦冬根提取物0.5份、土茯苓提取物0.1份、丹参根提取物0.1份、人参根提取物0.1份、缬草提取物1份、龙骨1份、尿囊素0.01份、EDTA二钠0.01份、甘油1份、丙二醇1份、丁二醇 1份、防腐剂0.01份、增稠剂1份、乳化剂0.5份、柔润剂1份、水30份、百合2份、首乌藤2份、苦参0.8份、茯神提取物2份、艾叶提取物2份、薄荷脑 0.5份、琥珀2份、牛油果树果脂10份、薰衣草油0.5份、檀香油0.5份、生育酚乙酸酯0.05份。
以上实施例中,防腐剂为对羟基苯乙酮,增稠剂为丙烯酸羟乙酯/丙烯酰二甲基牛磺酸钠共聚物,乳化剂为辛酸/癸酸甘油三酯,柔润剂为环五聚二甲基硅氧烷,但各材料不限于上述所述的组分,各材料还可以为本发明所记载的其它单个组分或者多种组分组成,并且各材料的组分份数不限于上述份数,各材料的组分份数还可以为本发明所记载的其它组分份数的组合,在此不再赘述。
对比例1:
对比例1是一种精油,采用茶树精油、檀香精油所制备而成。
对比例2:
对比例2是一种组合物,与实施例1的区别在于,对比例2的原料未使用γ-氨基丁酸。
对比例3:
对比例3是一种组合物,与实施例1的区别在于,对比例3的原料中所使用γ-氨基丁酸是使用常规方法所制备而成,如采用玉米浆的生物发酵法制备γ- 氨基丁酸。
对比例4:
对比例4是一种组合物,与实施例1的区别在于,对比例4的原料未使用人参根提取物。
对比例5:
对比例5是一种组合物,与实施例1的区别在于,对比例5的原料未使用龙骨。
对比例6:
对比例6是一种组合物,与实施例1的区别在于,对比例6的原料未使用缬草提取物。
对比例7:
对比例7是一种睡眠霜,与实施例7的区别在于,对比例7的原料未使用γ-氨基丁酸。
对比例8:
对比例8是一种睡眠霜,与实施例7的区别在于,对比例8的原料未使用酸枣仁提取物。
对比例9:
对比例9是一种睡眠霜,与实施例7的区别在于,对比例9的原料未使用麦冬根提取物。
对比例10:
对比例10是一种睡眠霜,与实施例7的区别在于,对比例10的原料未使用丙二醇、丁二醇。
1、产品渗透皮肤测试
(1)测试产品:实施例1
(2)实验方法
使用实施例1的产品,将其涂敷在手指上,在微循环测试仪观看手指血管血液流动情况;将手指上的产品擦干净后,再使用同样的实施例1的产品涂抹同样的部位,观看手指血管血液流动情况。
(3)实验结果,如图1、图2所示。
图1为手指第一次涂敷有实施例1的产品的末梢血管血液流动图,图2为手指再次涂敷有实施例1的产品的末梢血管血液流动图,从两个图中对比可知,图2的血管血液明显增快,可见,本发明的实施例1的产品可以有效改善微循环。
2、改善睡眠的测试实验
(1)人群的选择
选取25-45岁,失眠、多梦、具有睡眠障碍的人群,总人数为,420名,男女各210名。
(2)实验分组
选取志愿者中200名,男女配搭混合,涂敷本发明的实施例1-10的产品;选取志愿者中200名,男女配搭混合,涂敷对比例1-10的产品,其余20名志愿者不服用任何产品,作为空白对照组。
(3)试验方法
按照本发明所提供的使用方法:涂敷+按摩,每天睡觉前进行涂敷,连续服用一段时间,分为7天、10天、20天的观察期。
(4)改善睡眠的实验结果如下表1。
表1改善睡眠的实验结果
注:表中睡眠改善情况分为0、1、2、3等四种情况,0代表无明显改善;1代表稍微改善,能够入睡;2代表睡眠质量得到改善,能够中度睡眠;3代表睡眠质量很好,能够深度睡眠。
从表1中可看出,本发明所提供的组合物或者睡眠霜相互之间具有协同作用,在缓解焦虑、改善睡眠质量方面有着显著的效果。
3、具体实施例:
(1)尹某,男,43岁,IT行业,经常加班熬夜,睡眠不好,导致有高血压,但使用了本发明的实施例8的产品后,7天后,睡眠质量得到改善,能够安然入睡,17天后,能够达到深度睡眠。
(2)梁老师,女,39岁,白领,16岁的时候就开始睡眠质量不太好,几年后有了小孩,一旦中途醒来照顾孩子后,都需要1-2个小时才能入眠,但使用了本发明的实施例8的产品后,7天后,睡眠质量得到改善,中途醒来照顾孩子后,能在5-10分钟内入眠,20天后,能够达到中度睡眠。
(3)杨某,女,45岁,某化妆品的高层领导,由于工作压力大,经常晚睡,睡眠质量一般,并长期使用安眠药,辅助睡眠,但使用了本发明的实施例8的产品后,7天后,开始将安眠药的用量减少,10天后,安眠药的用量减半,20 天后,停药,并可以达到中度睡眠。
(4)李某,男,43岁,某保险公司职员,经常性睡眠不好,精神乏力,连续7天入睡前,使用了本发明的实施例8的产品后,睡眠质量得到了有效的改善。
(5)陈某,女,24岁,学生,因学习压力大,加上快要毕业找工作,晚上睡不好,白天没精神学习,导致脸上局部皮肤长痘,使用了本发明的实施例8 的产品后,7天后,脸上的皮肤慢慢变好,并且睡眠质量可以达到中度睡眠。
(6)蒋女士,52岁,家庭主妇,更年期综合征明显,潮冷潮热,易怒,长期性失眠,已经持续使用褪黑素三年多,但使用了本发明的实施例8的产品后, 7天后,开始将安眠药的用量减少,10天后,安眠药的用量减半,20天后,停药,并可以达到中度睡眠。
上述实施方式仅为本发明的优选实施方式,不能以此来限定本发明保护的范围,本领域的技术人员在本发明的基础上所做的任何非实质性的变化及替换均属于本发明所要求保护的范围。
Claims (10)
1.一种改善睡眠的组合物,其特征在于,包括如下重量份的组分:
γ-氨基丁酸0.2份-3份、酸枣仁提取物0.5-3份、麦冬根提取物0.5-5份、土茯苓提取物0.1-1份、丹参根提取物0.1-1份、人参根提取物0.1-2份、缬草提取物1-2份、龙骨1-5份。
2.根据权利要求1所述的改善睡眠的组合物,其特征在于,所述γ-氨基丁酸的制备方法是采用破壁技术和分子膜活化定向技术的结合,将甘蔗经过破壁、分离、提取、浓缩的步骤所制得。
3.根据权利要求1所述的改善睡眠的组合物,其特征在于,所述组合物还包括如下重量份的组分:百合1-3份、首乌藤1-3份、苦参0.5-1份、茯神提取物1-3份、艾叶提取物1-3份、琥珀1-3份。
4.根据权利要求1所述的改善睡眠的组合物,其特征在于,所述组合物还包括如下重量份的组分:牛油果树果脂5-15份、薄荷脑0.1-1份、薰衣草油0.1-1份、檀香油0.1-1份、尿囊素0.01-0.1份。
5.一种睡眠霜,其特征在于,包括如下重量份的组分:
γ-氨基丁酸0.2份-3份、酸枣仁提取物0.5-3份、麦冬根提取物0.5-5份、土茯苓提取物0.1-1份、丹参根提取物0.1-1份、人参根提取物0.1-2份、缬草提取物1-2份、龙骨1-5份、尿囊素0.01-0.1份、EDTA二钠0.01-0.1份、甘油1-3份、丙二醇1-3份、丁二醇1-3份、防腐剂0.01-0.1份、增稠剂1-3份、乳化剂0.5-2份、柔润剂1-3份、水30-60份。
6.根据权利要求5所述的睡眠霜,其特征在于,所述防腐剂为对羟基苯乙酮、羟苯甲酯中的一种或者多种组合;所述增稠剂为丙烯酸羟乙酯/丙烯酰二甲基牛磺酸钠共聚物。
7.根据权利要求5所述的睡眠霜,其特征在于,所述乳化剂为辛酸/癸酸甘油三酯、PEG-100硬脂酸酯、甘油硬脂酸酯、C14-22醇、C12-20烷基葡糖苷中的一种或者多种组合;所述柔润剂为环五聚二甲基硅氧烷、环己硅氧烷中的一种或者多种组合。
8.根据权利要求5所述的睡眠霜,其特征在于,所述睡眠霜还包括如下重量份的组分:
百合1-3份、首乌藤1-3份、苦参0.5-1份、茯神提取物1-3份、艾叶提取物1-3份、薄荷脑0.1-1份、琥珀1-3份、牛油果树果脂5-15份、薰衣草油0.1-1份、檀香油0.1-1份、生育酚乙酸酯0.01-0.1份。
9.一种睡眠霜的制备方法,其特征在于,包括如下制备步骤:
将百合、首乌藤、苦参投入超临界流体萃取装置,经过流体压缩、萃取、减压、分离的步骤,得到萃取液;
将龙骨、琥珀分别研磨粉碎后,过60目-80目筛,得到龙骨细粉和琥珀细粉;
将甘油、丙二醇、丁二醇、尿囊素、牛油果树果脂、生育酚乙酸酯、水放入乳化锅内,加热至70℃-80℃,均质10min-15min,冷却至40℃-50℃,形成第一混合物;
将酸枣仁提取物、麦冬根提取物、土茯苓提取物、丹参根提取物、人参根提取物、缬草提取物、茯神提取物、艾叶提取物、薰衣草油、檀香油、薄荷脑、萃取液、γ-氨基丁酸、乳化剂依次投入第一混合物,乳化均质30min-50min,形成第二混合物;
向第二混合物中依次加入防腐剂、柔润剂、EDTA二钠、龙骨细粉、琥珀细粉、增稠剂,搅拌混合10min-15min,冷却出料。
10.一种睡眠霜的使用方法,其特征在于,包括:
在睡觉前2h-3h,使用酒精棉将耳背、耳根、耳垂和额头擦干净,晾干;
对于轻度暂时性失眠者,挤出一颗黄豆大小的睡眠霜膏体,分成均匀的两部分,分别涂在两个耳背后面和耳垂前后侧;挤出一颗黄豆大小的睡眠霜膏体,沿着发际线均匀涂抹于额头上,按摩至吸收;按摩头部上的翳明穴和睡眠穴,揉并点按穴位,按摩时间为3min-5min;
对于重度暂时性失眠者,挤出一颗黄豆大小的睡眠霜膏体,分成均匀的两部分,分别涂在两个耳背后面和耳垂前后侧;挤出二颗黄豆大小的睡眠霜膏体,沿着发际线均匀涂抹于额头上,按摩至吸收;按摩头部上的翳明穴和睡眠穴,揉并点按穴位,按摩时间为10min-15min。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010014488.9A CN111195333A (zh) | 2020-01-07 | 2020-01-07 | 一种改善睡眠的组合物、睡眠霜及其制备方法和使用方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010014488.9A CN111195333A (zh) | 2020-01-07 | 2020-01-07 | 一种改善睡眠的组合物、睡眠霜及其制备方法和使用方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111195333A true CN111195333A (zh) | 2020-05-26 |
Family
ID=70741745
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010014488.9A Pending CN111195333A (zh) | 2020-01-07 | 2020-01-07 | 一种改善睡眠的组合物、睡眠霜及其制备方法和使用方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111195333A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111991256A (zh) * | 2020-09-04 | 2020-11-27 | 广东丸美生物技术股份有限公司 | 一种具有安神助眠功效的护肤基质及其制备方法和应用 |
CN113476551A (zh) * | 2021-07-13 | 2021-10-08 | 上海阶平医院管理有限公司 | 一种治疗失眠的磁疗液及其磁疗器 |
CN114762709A (zh) * | 2021-05-21 | 2022-07-19 | 品高生物科技(广州)有限公司 | 一种改善睡眠的植物精油及其制备方法和使用方法 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101804148A (zh) * | 2009-02-16 | 2010-08-18 | 北京因科瑞斯医药科技有限公司 | 一种具有改善睡眠功能的药物组合物及其制备方法 |
CN105725211A (zh) * | 2016-03-04 | 2016-07-06 | 广州万康保健品有限公司 | 一种用于改善睡眠的食品保健品及其制备方法 |
CN106138941A (zh) * | 2016-07-27 | 2016-11-23 | 长春中医药大学 | 一种改善睡眠和辅助改善记忆的中药复方制剂及制备方法 |
CN108671140A (zh) * | 2018-07-05 | 2018-10-19 | 天津益倍元天然产物技术有限公司 | 一种改善睡眠的组合物及其应用 |
CN109090609A (zh) * | 2018-09-17 | 2018-12-28 | 通化特立杰尔医药技术推广服务有限公司 | 一种安神助眠的组合物及其制备方法与应用 |
CN109331116A (zh) * | 2018-12-06 | 2019-02-15 | 青岛东海药业有限公司 | 一种组合物制剂及其应用 |
CN109331083A (zh) * | 2018-11-13 | 2019-02-15 | 温州浩然健康产业有限公司 | 一种助睡眠精华液及其制备方法和使用方法 |
CN109430866A (zh) * | 2018-10-31 | 2019-03-08 | 吉林省恒实传食品科技发展有限公司 | 一种镇静安神改善睡眠质量的健康养生食品配方及其制备方法 |
-
2020
- 2020-01-07 CN CN202010014488.9A patent/CN111195333A/zh active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101804148A (zh) * | 2009-02-16 | 2010-08-18 | 北京因科瑞斯医药科技有限公司 | 一种具有改善睡眠功能的药物组合物及其制备方法 |
CN105725211A (zh) * | 2016-03-04 | 2016-07-06 | 广州万康保健品有限公司 | 一种用于改善睡眠的食品保健品及其制备方法 |
CN106138941A (zh) * | 2016-07-27 | 2016-11-23 | 长春中医药大学 | 一种改善睡眠和辅助改善记忆的中药复方制剂及制备方法 |
CN108671140A (zh) * | 2018-07-05 | 2018-10-19 | 天津益倍元天然产物技术有限公司 | 一种改善睡眠的组合物及其应用 |
CN109090609A (zh) * | 2018-09-17 | 2018-12-28 | 通化特立杰尔医药技术推广服务有限公司 | 一种安神助眠的组合物及其制备方法与应用 |
CN109430866A (zh) * | 2018-10-31 | 2019-03-08 | 吉林省恒实传食品科技发展有限公司 | 一种镇静安神改善睡眠质量的健康养生食品配方及其制备方法 |
CN109331083A (zh) * | 2018-11-13 | 2019-02-15 | 温州浩然健康产业有限公司 | 一种助睡眠精华液及其制备方法和使用方法 |
CN109331116A (zh) * | 2018-12-06 | 2019-02-15 | 青岛东海药业有限公司 | 一种组合物制剂及其应用 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111991256A (zh) * | 2020-09-04 | 2020-11-27 | 广东丸美生物技术股份有限公司 | 一种具有安神助眠功效的护肤基质及其制备方法和应用 |
CN114762709A (zh) * | 2021-05-21 | 2022-07-19 | 品高生物科技(广州)有限公司 | 一种改善睡眠的植物精油及其制备方法和使用方法 |
CN114762709B (zh) * | 2021-05-21 | 2023-11-24 | 品高生物科技(广州)有限公司 | 一种改善睡眠的植物精油及其制备方法和使用方法 |
CN113476551A (zh) * | 2021-07-13 | 2021-10-08 | 上海阶平医院管理有限公司 | 一种治疗失眠的磁疗液及其磁疗器 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111195333A (zh) | 一种改善睡眠的组合物、睡眠霜及其制备方法和使用方法 | |
CN105213284A (zh) | 一种祛痘保湿霜及其制备方法 | |
KR101908978B1 (ko) | 스트레스 완화 및 피로 회복 효과를 갖는 향료 조성물 및 이를 함유하는 화장료 조성물 | |
CN109044941B (zh) | 一种皮肤紧致滋养保湿组合物及其制备方法和应用 | |
CN105193693A (zh) | 一种深海精华细致毛孔面霜及其制备方法 | |
CN106511211A (zh) | 一种抗炎祛痘护肤乳液及其制备方法 | |
WO2020140338A1 (zh) | 一种缓解疼痛复方精油及其制备方法与应用 | |
US20160101139A1 (en) | Topical treatment for use as a sleep aid | |
CN110882196A (zh) | 舒缓活力霜及其制备方法 | |
WO2018082117A1 (zh) | 具有祛除皮肤红血丝功能的外用中药组合物及其护肤制剂 | |
CN107441340B (zh) | 一种消肿止痛止痒滋养皮肤的手足皴裂膏及其制备方法 | |
CN105213285A (zh) | 一种祛痘洗面奶及其制备方法 | |
CN104887591A (zh) | 一种用于控油祛痘平疤的组合物 | |
CN104689292A (zh) | 兼具提神及杀菌消毒功效的复方精油 | |
CN107375613A (zh) | 一种具有袪除面部红血丝功效的中药提取物及其外用制剂 | |
CN102178813B (zh) | 瘦身美容型刮痧油及其制备方法 | |
CN105342923A (zh) | 一种预防嘴唇干裂的唇膏及其制备方法 | |
CN112656932A (zh) | 一种调节情绪因子改善亚健康的组合物及其制备方法 | |
CN112057386A (zh) | 一种清爽保湿美白修复的防晒乳及其制备方法 | |
CN105168103A (zh) | 一种细致毛孔深海鱼子精华液及其制备方法 | |
CA2620242A1 (en) | Topical soothing bruise healing preparation | |
CN105125465A (zh) | 一种祛斑洗面奶及其制备方法 | |
CN113694001A (zh) | 一种中药面膜膏 | |
CN110897964A (zh) | 舒缓活力乳及其制备方法 | |
CN115350260B (zh) | 一种用于皮肤具有助睡眠功能的日常护理生物制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200526 |
|
RJ01 | Rejection of invention patent application after publication |